Compare SRBK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRBK | EQ |
|---|---|---|
| Founded | 1887 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.6M | 129.0M |
| IPO Year | 2023 | 2018 |
| Metric | SRBK | EQ |
|---|---|---|
| Price | $18.85 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 57.3K | ★ 878.7K |
| Earning Date | 04-28-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 138.36 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $60.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.81 | $0.29 |
| 52 Week High | $19.61 | $3.45 |
| Indicator | SRBK | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 54.53 |
| Support Level | $16.24 | $1.70 |
| Resistance Level | $19.07 | N/A |
| Average True Range (ATR) | 0.33 | 0.37 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 77.78 | 55.69 |
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.